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INTRODUCTION 
 
Focal segmental glomerulosclerosis (FSGS) is a common cause of 
nephrotic syndrome, accounting for 10% to 35% of nephrotic syndrome in 
adults 1. Focal segmental glomerulosclerosis is a pattern of injury defined by a 
segmental scar, that involves some but not all glomeruli. The prognosis  of  
FSGS in untreated patients is poor , with 50%  patients reach   end-stage renal 
disease  (ESRD) at eight years. FSGS account for 20% of dialysis patients and   
is a common cause of  ESRD.  The incidence of FSGS has been increasing in 
recent years. Kitiyakara et al. reported an 11-fold increase in FSGS among 
dialysis patients older than 21 years 2 . Treatment with  steroids for 1-2 months  
has  minimal  effect on outcomes. Studies have shown that , high-dose 
glucocorticoids  for longer periods of more than five months improved   
remission  rate  from 15% to 50% 3 .  Patients with primary FSGS  treated with 
prednisolone , are more likely to enter remission than untreated one. Remission 
rates of  80% can be  achieved with  longer treatment, and is an independent 
predictor of renal survival  4. Five pathologic variants of idiopathic focal 
segmental glomerulosclerosis 5 : collapsing , cellular , tip lesion , perihilar, and 
not otherwise specified  . Not Otherwise Specified  is the most  common histo-
pathological subtype reported in most of the series.  
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                              In adults,  responsiveness  to steroids usually  take up to 16 
weeks, and   can be slowly tapered over three to six  months. Therapy for 
steroid-resistant FSGS  is  calcineurin inhibitor, either cyclosporine or 
tacrolimus. Patients who have persistent  proteinuria are also  at high  risk of 
cardiovascular morbidity and mortality.  FSGS can be broadly classified into 
primary , secondary , syndromic , and familial 6. 
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AIM AND OBJECTIVES 
       
1. To study the epidemiological profile of  primary  focal segmental 
glomerulosclerosis in adults. 
2. To study the clinicopathologic correlation and prevalence of subtypes of  
FSGS , according to Columbia classification. 
3. To evaluate the response to treatment, predictors of  poor response and risk 
factors in the progression to chronic kidney disease in these patients. 
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REVIEW OF LITERATURE 
1.DEFINITION  
Focal segmental glomerulosclerosis is defined as segmental increase in 
mesangial matrix with obliteration of the capillaries, sclerosis, hyalinosis, foam 
cells, and segmental scarring , and  adhesion between the glomerular tuft  and 
Bowman’s capsule  involving less than 50% of glomerulus and affecting less 
than 50% of glomeruli 7 . This is  characterized by marked  proteinuria,  steroid 
resistance, hypertension, and a higher progression8  to chronic kidney disease 
(CKD). The diagnosis of primary FSGS  is usually  made with typical  lesion 
involving some of the glomeruli  with others remaining uninvolved in the renal 
biopsy, with  no clinical or pathological evidence of disease that might produce 
secondary FSGS. 
2. INCIDENCE  
The incidence of FSGS among children with nephrotic syndrome  was  
10% in less than six years, reaches upto 20–50% in the adolescence. It accounts 
for 20 - 25% of idiopathic nephrotic syndrome in adults 9 . Recent reports reveal  
upto an eightfold raise in the incidence of FSGS in the  past two decades. An 
observational study showed that FSGS was found in 2.5–4% of renal biopsies in 
1970s and  increased to 12.2–18.7% in 1990s 10 . FSGS is becoming  the 
commonest disease  in native kidney biopsies and is  the most common primary 
glomerular disease causing ESRD in the United States 11 and  its prevalence was 
4%.  
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3.HISTORY  
Theodor Fahr was the first to describe FSGS  in 1925  in adult nephrotic 
patients 12. However , Arnold Rich 13 was the one who clearly defined the 
histological lesion in nephrotic children in 1957.  Later Jack Churg, Rene Habib 
and Richard, pathologists of International Study of Kidney Disease in Children , 
reported  the presence of this type of lesion  in renal biopsies taken from 1966 to 
1969 in  childhood nephrotics 14,15.  
    
4.CLASSIFICATION                        
Classification of  FSGS  include primary , genetic and secondary. 
Primary (Idiopathic)  occurs without known inciting injury 16. Secondary FSGS  
occurs in association with human immunodeficiency virus (HIV) infection 17 , 
parvovirus, cytomegalovirus, drug toxicity (pamidronate, interferon, lithium, 
anabolic steroids) ,  malignancies and heroin nephrotoxicity   and immune 
complex diseases. The commonest type of secondary FSGS is included under  
adaptive or hyperfiltering FSGS. Alteration in glomerular hemodynamics, 
resulting in afferent arteriolar vasodilation and increased intracapillary 
hydrostatic pressure is the cause behind  these types of FSGS. 
 
Adaptive FSGS include 
Conditions with reduced renal mass: oligomeganephronia, , unilateral 
renal agenesis, renal dysplasia, reflux nephropathy, low birth weight, surgical 
renal ablation, aging kidney ,renal allograft. 
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Conditions with  normal renal mass: systemic hypertension, acute or 
chronic vaso-occlusive processes (thrombotic microangiopathy, renal-artery 
stenosis, atheroembolization) , sickle cell anemia , obesity,cyanotic congenital 
heart disease.  Obesity-related FSGS is currently the most frequent type of 
secondary FSGS 18,19. 
Genetic causes include defects affecting the expression and function of   
proteins  podocin (NPHS2) , nephrin,  alpha-actinin-4,  TRPC6,  CD2AP, 
synaptopodin that present in slit  diaphragm and podocyte  20 . Early onset of 
disease and a family history of nephrotic syndrome should arise the suspicion of 
genetic FSGS. Nephrin (NPHS1) was first cloned  in  congenital nephrotic 
syndrome of the Finnish type 21 .    
The NPHS1 gene is present on  chromosome    19q13 and encodes for 
Nephrin. The protein nephrin is  a 185 kDa  protein with an intracellular,  single 
transmembrane  and extracellular domain. Subsequently, additional genes 22 
including podocin, alpha-actinin-4 (ACTN4/FSGS1),transient receptor potential 
cation channel, type 6 (TRPC6/FSGS2), CD2- associated protein 
(CD2AP/FSGS3)  and phospholipase c E1 (PLCE1/NPHS3) as causes for 
hereditary nephrotic syndromes (FSGS)  23,24  have been identified.  Podocin 
mutations  are responsible for the autosomal recessive (AR) form of steroid-
resistant nephrotic syndrome.d Podocin is a 42-kD transmembrane protein  
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present in  podocytes that consists of a short extracellular domain followed by a 
transmembrane-spanning region and a long cytoplasmic tail.  
 
5.PATHOLOGY 
 
The confirmation of FSGS is essentially done by renal  biopsy .Light 
microscopy shows  focal  and segmental solidification of the glomerular  tuft, 
adhesion of the tuft to the Bowman capsule (synechiae) , hyalinosis, 
intraglomerular  foam cells ,hypertrophy of podocytes, bridging of parietal cells, 
focal interstitial fibrosis and tubular atrophy and minimal inflammation, 
restricted to the areas of fibrosis 25  . On immunofluorescence, there is  focal and 
segmental  staining  of immunoglobulin M, C3, and occasionally C1q  in the 
areas  of sclerosis and hyalinosis. Staining for albumin  may be found within the 
podocytes, corresponding to intracytoplasmic protein resorption droplets. 
 
In electron microscopy, the lesions of segmental sclerosis show wrinkling 
and retraction of glomerular basement membrane (GBM) and accumulation of  
hyaline within the membrane, resulting in  occlusion of the glomerular capillary 
lumina 26 . Hyaline deposits  contain membranous particles or electron lucent 
lipid globules. Intraglomerular  foam cell appears  as large intracapillary cell  
that contain electron lucent vacuoles .Variable degree of foot process 
effacement is seen directly overlying the lesions of segmental sclerosis. Focal 
aggregation of the actin filaments  against the abluminal surface of podocytes 
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accompanied by podocyte  hypertrophy, increased organellar content will also 
be seen. Focal microvillous transformation  is due to the formation of thin  
cellular projections that resemble villi along the surface of  podocytes . 
Hypertrophied podocytes  may adhere smoothly to or focally detached from  
GBM with interposition of newly formed extracellular matrix. 
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  A working group has defined five subtypes of focal segmental 
glomerulosclerosis 27  based on light microscopic assessment (Columbia 
classification) which include  
Collapsing FSGS  - this is defined as collapse of at least one capillary loop 
accompanied by  obliteration of the lumen with hyperplasia and hypertrophy of 
the overlying podocytes , regardless of the presence or absence  of other lesions. 
In contrast to original description,working classification does not include  
tubulointerstitial changes for the diagnosis of this variant.  
Tip lesion – This variant is diagnosed by  exclusion of collapsing  FSGS with  
at least one glomerulus with segmental lesion involving the tip of the 
glomerular capillary . A segmental lesion is defined as the presence of 
endocapillary hypercellularity (involving  < 50% of the tuft), or sclerosis ( of  < 
25% of the glomerlar tuft)  and foam cells. The tip domain is  defined as the 
outer 25% of the glomerulus next to proximal tubular origin. 
Cellular Variant – For diagnosis  of this type the exclusion of  collapsing and 
tip variant of FSGS is necessary. It  is defined by  the presence of at least one 
glomerulus with segmental endocapillary proliferation occluding the  lumina 
28,29 .This may be accompanied  with or without karyorrhexis . ce to treatment 
Perihilar variant – this is defined as the segmental sclerotic lesion with or 
without hyalinosis   at the vascular pole usually opposite to the tubular pole  . 
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Presence of all other  lesions like tip, cellular or  collapsing within the same 
biopsy should be excluded before making a diagnosis of this variant. 
Not Otherwise Specified or NOS  is  diagnosed when all other lesions by 
definitions are excluded. Segmental solidification of the glomerular tuft in any 
portion of the glomerulus usually  accompanied by adhesion of the tuft to the 
Bowman’s capsule is seen in this variant. 
 
6.PATHOPHYSIOLOGY  
 
 
The  key  pathogenesis of FSGS is podocyte damage and loss. Injury to 
podocytes occurs by four  mechanisms : alteration of the slit diaphragm or 
interference with its structure, dysregulation of  the actin based cytoskeleton, 
alteration of the GBM  or its interactions with the podocyte, or alteration of the 
negative charge of the podocyte surface. These  progressive changes lead to  
foot process effacement and  apoptosis of podocyte, formation of synechiae, 
filtration of non-specific plasma proteins, misdirected filtration at points of 
synechiae, capillary expansion and  mesangial matrix expansion 30,31 .These 
summary of events are given below. 
 
 
12 
 
 
                                        Cytokines and vasoactive substances also play a role in 
the progression of FSGS. In animal model, overexpression of transforming 
growth factor β  and  its effector proteins , Smads  lead to glomerulosclerosis. 
Cytokines lead  to  recruitment of  monocytes, macrophages,  and T-cells. This 
inturn  stimulates  interleukin-1, tumor necrosis factor alpha, and chemokines . 
Platelet derived growth factor  and vascular endothelial growth factor  also play 
a role in the  progression of disease. The inflammatory infiltrate leads to 
mesangial matrix deposition, promoting the collapse of glomeruli. Cellular 
infiltrates and cytokines damage tubular epithelial cells, and  these  cells may 
undergo transformation to mesenchymal cells ( called as  epithelial- 
mesenchymal transition or  EMT) .  The presence of plasma proteins in the 
glomerular  filtrate also causes direct injury to the tubulointerstitium. The 
mesenchymal cells  and the   recruited , stimulated fibroblasts,  cause  matrix 
deposition and tubulointerstitial fibrosis31,32 .  
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Two genes, MYH9 that encodes myosin heavy chain 9 which is a 
component of podocyte and APOL1 were identified on chromosome 22 and its 
role related to FSGS were described recently 33,34  .aAPOL1 with G1 and G2 
variants  was identified  as the susceptibility gene and act  on  podocyte  
mechanistically (seen commonly in Africo-Americans ) .to cause FSGS 35 . 
    Cardiotrophin-like cytokine 1 is a member of interleukin-6 family with a 
molecular weight of  < 30 kDa . CLC1 and soluble urokinase receptor (SUPAR) 
are implicated in patogenesis of FSGS 36 .Circulating SUPAR  induces foot 
process effacement by activating  β3 integrin in podocyte . Serum levels of  
more than  3000 pg /ml  were documented in two thirds of patients with 
idiopathic FSGS but not in minimal change disease 37  . 
Still there is a debate whether  FSGS and minimal change disease (MCD) 
is continuum of single entity or different diseases.The support  to the identity of 
the two diseases is the repeated description of some patients with initially 
steroid-sensitive disease and minimal change on histology, who evolve to FSGS 
and  develop corticosteroid resistance, end-stage renal disease and  sometimes 
recurrent disease. Intense immunosuppression can on occasion cause remission  
in  patients with renal impairment and FSGS 38  . But more recent advances 
show difference in pathogenesis of both the entity with involvement of 
circulating factors in the pathogenesis of FSGS  and early recurrence of FSGS 
after renal transplantation.An essential difference between these two entities is 
14 
 
that  rearrangement of  actin cytoskeleton, typically reverse with  steroid  
therapy in MCD but irreversible and progressive in FSGS. 
Recently FSGS is included under umbrella term ‘podocytopathy’  with 
common pathophysiologic principle of absolute or relative podocyte depletion  
and injury 39 . 
 
 
                                 
 
 
 
 
7.ANIMAL MODEL 
Animal model of FSGS  include BALB/c mice  with doxorubicin induced 
lesions 40  and Th Buffalo/mna rats . Another one is the mouse model with 
puromycin aminonucleoside  nephrosis.In vitro studies showed  enhanced 
permeability of glomerulus  to albumin and  transient proteinuria  when serum  
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from FSGS patients were  injected into Sprague-Dawley rats 41,42 . This 
confirms the presence and implication of circulating factors in the  pathogenesis 
of FSGS.b it R fl 
 
8.CLINICAL PRESENTATION 
                                    
Nephrotic syndrome  is  usually  present in 60%  at onset and may 
increase upto 80–90% with time  43 . Secondary FSGS rarely present with a full 
nephrotic syndrome, and typically  slower in  onset , with less proteinuria , 
preserved serum albumin ,and less edema. In primary FSGS, macroscopic 
haematuria is very rare, but usually associated with micro-hematuria (50%), 
hypertension (60%), and decreased kidney function (25%-50%) 44 .  Proteinuria  
in FSGS is predominanty nonselective compared to selective proteinuria in 
MCD 45 . 
 
9.CLINICOPATHOLOGICAL CORRELATION 
Schwartz and Lewis  29 in 1985, recognized that patients with the cellular 
lesion were more often present with nephrotic syndrome than classic FSGS 
patients . Howie et al. found  that patients with  tip lesion  46  experienced  48% 
remission with prednisolone , and  10-yr renal survival  rate of 90%  . However, 
in the  remaining non-remitters (52%)  , the 10-yr renal survival was 30%. 
Stokes et al. showed that  the presentation , course and outcome in tip variant  
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was  similar to MCD 28 .Remission  was  highest for  tip variant, intermediate 
for NOS variants,  cellular and perihilar and least for  collapsing FSGS. 
 
10.TREATMENT 
Immunosuppressive  agents are  the mainstay of treatment in primary 
FSGS which include steroids, calcineurin inhibitors, cytotoxics whereas a 
conservative approach is  recommended in genetically-determined FSGS as  
immunosuppressants are not usually effective in these group 47 .    
The  main aim of therapy is  the induction of remission of proteinuria  
either complete or partial with better preservation of  kidney  function. Even 
achievement of  partial remission improves the long-term renal survival. Steroid 
therapy is the first line of therapy unless the side effects of glucocorticoid 
therapy like  diabetes, psychiatric disorder, or severe osteoporosis, where 
calcineurin inhibitor  will be the initial choice of treatment . 
                   Treatment of primary FSGS in adults must be graded according to the 
presence or absence of  factors affecting prognosis adversely . One  meta-
analysis revealed CR in 61%  who were treated  for longer periods with 
prednisolone  , whereas it was  15%  in those with shorter duration (< 4 
months). Most  of  the patients attained  remission after six months. Higher 
remission rate was observed in patients treated  approximately for   5–9 months  
than shorter duration 48 . 
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GLUCOCORTICOIDS 
Glucocorticoids bind to the steroid receptor in the cytoplasm and 
translocate to  nucleus where they bind to glucocorticoid response elements  
(GRE)  on the DNA strand. Glucocorticoid receptors  are  also expressed in  
podocytes and translocate to the nucleus  after steroid treatment. Thus   
glucocorticoids  have a  direct effect  on podocytes in the treatment of nephrotic 
syndrome . Ransom et al. demonstrated that dexamethasone  leads to increased 
expression of ciliary neurotrophic factor,  heat shock protein 27  and  αB-
crystallin on podocytes. 
CYCLOPHOSPHAMIDE 
Cyclophosphamide  is an alkylating agent that affects lymphocytes  
nonspecifically , hence more prone for infections.Twenty  two percent of FSGS 
patients  with steroid-resistance achieved remission  due to cyclophosphamide 
in one study  while others have  shown  a much  lower effectiveness 49. 
CYCLOSPORINE   
Cyclosporine A (CSA) binds to cytosolic cyclophilin and inhibits protein 
phosphatase calcineurin .Thereby CSA blocks the signal transduction of  factors 
like NFAT and NF-k B, essential for the induction of cytokines and  activation 
of T-lymphocytes. CSA suppresses predominantly  the cellular immunity and 
have minimal action on humoral pathway .  Role of  cyclosporine  in FSGS is 
due to its direct effect on the filtration barrier by stabilising synaptopodin in the 
podocyte 50 . 
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In a randomized trial  by National Institute of Health (NIH) ,12-month 
course of cyclosporine was compared  with a combination of oral pulse 
dexamethasone and MMF in glucocorticoid- resistant children and adults up to 
40 years of age 43 . Remission either complete or partial  occurred in 46% of  
CSA group whereas only 33%  achieved remission   in the other group ,which 
was not statistically significant different .  
TACROLIMUS 
Tacrolimus is an immunosuppressive agent, that inhibits T cells 
activation49 .  It binds to a FKBP, a receptor in the cytoplasm of  T cells  and 
inhibit signal transduction.The effect of Tacrolimus in FSGS is  probably by 
stabilising the slit diaphragm proteins.  
MYCOPHENOLATE MOFETIL                                 
Mycophenolate mofetil (MMF)  is a prodrug  and its active metabolite 
mycophenolic acid  inhibits the inosine monophosphate dehydrogenase  which 
is essential for  purine  synthesis . Role of  MMF in steroid resistant cases of 
FSGS  51  are recently evaluated and found to be beneficial.  
RITUXIMAB 
Rituximab is a chimeric monoclonal antibody  that targets CD20 on  the 
surface of B cells and causes cell damage by complement dependent and 
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independent mechanisms. Case reports and small case series have shown benefit 
of rituximab in posttransplant recurrence  of FSGS .  Fresnedo  et al 52 , showed 
a moderate  response to rituximab in steroid resistant FSGS . 
ORAL GALACTOSE  
Savin et al.  hypothesised that administration of large amounts of 
galactose to patients 36 with  FSGS  might cause  formation of circulating 
complexes of free galactose and  circulating factors that could be cleared by  
liver preventing these factors  from interacting with the glycocalyx in GBM. 
Apart from immunosuppression agents , supportive therapy like diuretics 
for edema, treatment of proteinuria with renin-angiotensin system  blockade and 
control of blood pressure and hyperlipidemia should be given 53. 
11.OUTCOME AND PROGNOSIS 
In patients with primary glomerulonephritis, renal survival is clearly 
lower for FSGS than for IgA nephropathy and membranous nephropathy. 
Retrospective studies have suggested that complete remission may occur in up 
to 60% of patients after prolonged treatment with immunosuppressive drugs. 
Hence, a trial of steroid therapy is recommended in all patients with primary 
FSGS 54 . 
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Around 50% to 70% of  FSGS patients  may  need regular dialysis or die 
due to uremia  at 10 years after diagnosis. In one report , outcomes showed  
30% of  adult patients with idiopathic FSGS developing renal failure at  5 years 
. Massive proteinuria at the time of  presentation or during the course  carries a 
poor long-term prognosis. Age , raised  serum creatinine at the time of 
diagnosis, hypertension,  heavy smoking and advanced interstitial fibrosis are 
the factors that increase the risk for CKD 55 . The most powerful  predictor of  
progression to CKD in FSGS  is the treatment response . Male  and  African 
race  confers 4-fold higher  risk for ESRD progression . Wehrmann and 
colleagues 56  found an overall 10- year kidney survival of 67%. 
 Information about  prognostic factors is useful to advise patients  about  
the probable outcome of disease, selecting therapeutic options . Remission  was 
associated with a 5-year  renal survival of  94%, compared with 53%  if 
remission was not achieved . The prognosis of untreated nephrotic patients is 
poor, with 50% developing end-stage renal failure within 8 years. 
Prognosis is poor in patients  not  achieving  remission, with 5 -year 
kidney survival of  65%  (60–90%)  and 10-year kidney survival of  30%              
(25–56%) 57 . Kidney survival rates were 90.4%, 69%, and 47% at 1, 5 and 10 
years of follow-up in a cohort of children with FSGS 58  . Females have a better 
outcome than males in FSGS . Spontaneous remissions are very uncommon and  
21 
 
occur in less than 5% of patients 59  . Persistent nephrotic syndrome and renal 
insufficiency at presentation are independent risk factors for poor prognosis. 
 
12.RENAL TRANSPLANTATION AND RECURRENCE:   
                    Post-transplant FSGS recurrence is defined by  histopathologic diagnosis 
ascertained before transplantation, profuse proteinuria appears early after  
transplantation ,and graft  biopsy reveals  the reappearance of FSGS weeks later. 
Recurrence  occurs in 32% to 48% after transplantation .Thirty  percent of  
patients with FSGS have recurrence of proteinuria  after transplantation , and in 
80% of those patients who have previous graft loss due to recurrent FSGS 60. 
Recurrence of proteinuria may begin within 1 week after transplantation in 
around 70 % . Michelle A.Baum et al. showed six  year survival after 
transplantation to be lower in FSGS with   higher recurrence rate . Recurrence 
of FSGS  often causes graft dysfunction (in 20 - 30% of patients) or graft loss 
(in 40 -50% of patients).  
Age ( younger ) at onset of disease, non-black race, rapid progression  to  
ESRD  within  three years , heavy proteinuria prior to transplantation, and 
previous allografts loss  due to recurrence are risk factors for the recurence of 
disease 61 . Plasmapheresis or immunoadsorption have been shown to reduce 
proteinuria successfully and to interrupt the progression of renal insufficiency in 
recurrent disease in allograft. 
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METHODOLOGY 
STUDY POPULATION 
Adult  patients (age group between 13-60) who were diagnosed to have 
biopsy  proven  FSGS  and treated  at  Department of  Nephrology at Rajiv 
Gandhi Government General hospital between 2006 January and  December 
2012  were included .  
 
INCLUSION CRITERIA 
All  patients who have biopsy proven FSGS and treated with oral 
prednisolone  for  24 weeks with atleast 6 months followup  were included after 
getting written consent.  
 
EXCLUSION CRITERIA  
1. Patients with secondary causes of FSGS  and those with family history 
FSGS and renal    disease 
2. Patients not willing for steroid therapy, poor compliance with drugs and 
followup with less than six months  
3. Creatinine clearance less than 25ml/min/1.73m2. 
 
SUBJECTS AND METHOD 
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Demographics like  age , gender, body mass index (BMI) , clinical 
symptoms and signs co-morbidities  based on detailed history of  the included 
patients were noted. Detailed clinical examination and blood pressure 
measurements were performed. Laboratory  parameters  included  were 24-hr 
urine protein, urine examination findings , serum creatinine, blood urea, serum 
albumin and lipid profile at the onset of disease. Creatinine clearance (Crcl)  
was  calculated with Cockraft Gault equation and expressed in ml/min/1.73 m2. 
 
RENAL BIOPSY 
 
Renal biopsy was performed on all patients with adult onset nephrotic 
syndrome . The diagnosis of FSGS was made when at least one glomerulus 
show a typical   sclerotic lesion in a segment in light microscopy. Renal biopsy 
tissue was processed for light microscopy and immunofluorescence. Subtyping 
of  FSGS  was performed  in according to  Columbia classification described by 
D’Agati. This include FSGS NOS, tip variant, perihilar variant, cellular  and 
collapsing variant. Histologic features like global glomerulosclerosis, mesangial 
proliferation (>3 cells in a mesangial area, away from vascular pole) , 
intraglomerular foam cells and arteriolar changes (presence or abscence of 
arteriosclerosis) were studied . The interstitial fibrosis and tubular atrophy were 
graded as mild (<25% ), moderate (26-50% ) and severe (>50% ) of cortical 
parenchymal involvement. Biopsies with significant staining for IgG and IgA 
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were excluded from the study. Clinicopathologic correlation were assessed 
based upon the renal biopsy findings after excluding secondary FSGS with 
extensive search for secondary causes. 
 
TREATMENT AND FOLLOWUP 
    All patients are started on oral prednisolone 1 mg/kg/day after the 
infections were ruled out and continued for 6 months , tapered  and stopped  
within one month. If the patients did not respond to steroids at 6 months, they 
were started on one of the following second-line drugs that include oral 
cyclophosphamide, cyclosporine, tacrolimus or MMF. All patients were 
received maximal tolerable dose of angiotensin-converting inhibitors (ACEI) or 
angiotensin II receptor blockers (ARB). HMG coenzyme A reductase inhibitor 
atovastatin 10-20 mg/day were also given. Supportive treatment like diuretics 
and antihypertensive drugs were also used whenever required. 
 
All  the subjects  were monitored every  two weeks for initial  two 
months, monthly for  next 4 months and  quarter yearly thereafter. Patients were 
examined  for  the presence of  edema, hypertension and infections at every 
visit. Any complications either due to disease process or treatment were noted. 
Urine routine, urine protein creatinine ratio and serum creatinine were 
monitored at each visit. Serum albumin, and fasting lipid profile were 
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monitored every 3 months. Total blood count was measured  every  two weeks 
if the patient was on  cyclophosphamide or MMF therapy. Serum creatinine 
level  were checked weekly in the 1st month, then fortnightly  for  six months 
and monthly thereafter for the patients receiving calcineurin inhibitors. When 
the patients relapse after complete or partial remission ,they were treated with 
steroids or second-line drugs. 
DEFINITIONS USED 
1. Hematuria – presence of > 2 RBCs in spun urine 
2. Nephrotic proteinuria – urine protein > 3.5 gms/day 
3. Hypertension – systolic blood pressure (BP) >140 mm Hg & diastolic BP 
> 90 mmHg 
4. Anemia – blood hemoglobin < 11 gm/dl 
5. Hypoalbuminemia – serum albumin < 3.5 gm/dl 
6. Hypercholesterolemia – serum total cholesterol > 200 mg/dl 
7. Renal failure –  Crcl   less than 60 ml/min/1.73 m2 
8. Complete remission (CR) -  proteinuria <0.3 g/ day with a stable serum 
creatinine  (<50% increase from baseline)  
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9. Partial remission (PR) - proteinuria between 0.3 g/day  and 3.5 g/ day 
with at least 50% reduction in proteinuria from baseline and a stable 
serum creatinine  
10. No remission (NR) – absence of complete or partial remission 
11. Relapse - proteinuria >3.5 g/24 h after prior complete or partial remission  
12. Chronic kidney disease – Crcl < 60 ml/min/1.73 m2  after three months 
13. ESRD  - Crcl < 15 ml/min per 1.73m2  or the need for dialysis or renal  
transplantation.  
TYPE OF STUDY 
                   Simple retrospective and prospective study 
STATISTICAL ANALYSIS 
All the variables were expressed in mean ± SD  or percentage. Univariate 
analysis was done by  Fisher’s exact and chi-square test for categorical variables  
and analysis of variance (ANOVA) was used for continuous variables. 
Statistical significant variables by univariate analysis were subjected to Linear 
regression analysis to assess multivariable association. Renal  survival  rate  was 
determined by the Kaplan-Meier method . The log-rank test was used to 
evaluate the significance of the difference between survival mean in subgroups. 
In all analytic procedures, a p <0 .05 was considered significant . 
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                                                RESULTS 
 
 
Among 195 adult patients (13-60 years) diagnosed to have biopsy proven 
FSGS between 2005-2012 , 170 were included in the study after applying 
exclusion criteria. In 25 excluded patients , five patients had stopped steroid 
therapy due to complications , four lost followup before six months and 16 
patients had secondary causes of FSGS. Mean duration of follow up was 4.32 ± 
1.2 years.About 65 % were males ( Male:Female ratio -  111:59 ,1.9:1) . 
Baseline patient characteristics at the time of biopsy are shown in Table 1. 
 
Table 1-BASELINE CHARACTERISTICS MEAN S D RANGE 
AGE (Years) 29.2 13.1 13-60 
SYSTOLIC BLOOD PRESSURE(mm Hg) 132 45 90-220 
DIASTOLIC BLOOD PRESSURE(mm Hg)  84 23 60-120 
BODY MASS INDEX 24.7 13 20-29 
PROTEINURIA(grams/day) 4.26 1.9 1.5-9 
SERUM CREATININE(mg/dl) 1.24 0.56 0.6-5 
CREATININE CLEARANCE(ml/min) 85.8 34 30-140 
HEMOGLOBIN(gm/dl) 11.6 4.5 7-15 
SERUM CHOLESTEROL(mg/dl) 215 111 118-540 
SERUM ALBUMIN 3.4 0.7 2.5-4.2 
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AGE  
The predominant age group  in our study was between 21-40 years  
accounting for 54% of total patients .    Figure 1 gives age distribution among 
study group. 
Figure 1 
 
 
CLINICAL PRESENTATION:   
The most common symptom was edema (98%). Sub- nephrotic 
proteinuria (defined as urine protein < 3.5 gm/day) was seen in  35 patients (21 
%). History of smoking was present in 27 patients (16%). Prevalence of anemia 
was 36%. Hypercholesterolemia and hypoalbuminemia were noted in 91 
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patients (54%) and 97 patients (57%) respectively.Type of clinical presentation 
are shown in below Table 2. 
    
 
             
 
 
 
 
 
 
Table 2-PRESENTATION NO OF PATIENTS (N-170) PERCENTAGE
EDEMA 167 98 
NEPHROTIC PROTEINURIA 135 79 
SUB-NEPHROTIC PROTEINURIA 35 21 
MACROHEMATURIA 2 1 
MICRO-HEMATURIA 52 30 
HYPERTENSION 70 41 
RENAL INSUFFICIENCY 34 20 
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RENAL BIOPSY 
                                 All the patients underwent percutaneous renal biopsy . 
Mean number of glomeruli in the renal biopsy were 10 ± 2. Biopsy specimens 
with more than 10 glomeruli were considered adequate.Histological 
characteristics are given in Table 3. 
 
Table 3-CHARACTERISTICS 
NO OF 
PATIENTS 
( %) N-170 
NO OF GLOMERULI >= 10 120(71) 
GLOMERULAR SCLEROSIS 
                   ABSENT 
                    0-25% 
                    26-50%      
                    >50%               
 
106(62) 
48(28) 
13(8) 
3(2) 
MESANGIAL 
HYPERCELLULARITY
18(11) 
PRESENCE OF FOAM CELLS 44(26) 
INTERSTITIAL FIBROSIS 
&TUBULAR ATROPHY 
                    ABSENT 
                       <25% 
                        26-50% 
                        >50% 
 
 
25(14) 
97(57) 
37(22) 
11(7) 
PRESENCE OF 
ARTERIOSCLEROSIS 
94 (55) 
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In immunofluorescence, 90 patients (53 %) showed IgM positivity and 56 
patients (33%) had C3 positivity usually 1 +. 
 
TREATMENT 
 
All the patients were started on antiproteinuric measures with angiotensin 
converting enzymes inhibitors (ACEI) or angiotensin receptor blockers (ARB) 
or both and escalated to a maximum tolerable dose ,out of which 14 patients 
(8%) were off drugs due to intolerance. Immunosuppression include oral 
prednisolone for all patients and second-line in steroid resistant patients 
whenever indicated and is  given in figure 2. 
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Figure 2 
 
Figure 3 
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COMPLICATIONS 
Venous thrombosis and cellulitis due to anasarca occurred as 
complications of  disease process.Infection is the  commonest complication 
followed by cushingoid features due to drugs. Two patient suffered from 
glaucoma and 8 from cataract due to steroid therapy. Complications during 
followup are summarised in figure 3.   
FOLLOWUP AND OUTCOME  
The mean followup duration  was 4.32 years.Mean values of proteinuria , 
serum creatinine and creatinine clearance on followup are given in table 
4.About 49 % of patient progressed to CKD at mean followup.  
Table 4 
MEAN 
PROTEINURIA
(gm/day) 
MEAN 
CREATININE
(mg/dl) 
MEAN 
CRCL(ml/min/
1.73 m2) 
PATIENTS 
WITH 
CKD (%) 
PATIENTS 
WITH  
ESRD 
cumalative 
% 
AT 3 
MONTHS 2.18 1.13 87 21/170(12) - 
AT 6 
MONTHS 1.67 1.43 83 22/170(13) - 
AT 12 
MONTHS 1.5 1.28 78 31/165(19) 1(0.5) 
AT 3 
YEARS - 1.7 64 47/111(42) 7(4) 
AT 5 
YEARS - 2.1 55 46/76 (60) 25(15) 
AT MEAN 
FOLLOWUP - 2.35 58 84/170(49) 29(17) 
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Response to treatment as defined previously are expressed as CR ,  PR  
and  NR  and details of other immunosuppression therapy are described in Table 
5. Incidence of ESRD is 29 (17%) at mean time of 4.32 years and two patients 
died due to uremia at mean time of  2.4 yrs.   
 
 
 
Table 5 NO OF PATIENTS(%) MEAN 
DURATION(MONTHS) 
PREDNISOLONE 
PARTIAL REMISSION(PR) 
    OVERALL 
     PR ALONE 
    PR FOLLOWED BY CR 
COMPLETE REMISSION 
NO REMISSION(NR) 
 
OUT OF 170 
93(55) 
39(23) 
54(32) 
54(32) 
77(45) 
 
 
4.5 
5.7 
3.4 
6.4 
51 
CYCLOPHOSPHAMIDE 
        PR/CR 
OUT OF 6 
NIL 
 
4 
CYCLOSPORINE 
         PR 
         NR 
OUT OF 3 
2(66) 
1(34) 
 
5.5 
6 
TACROLIMUS 
        PR 
OUT OF 2 
2(100) 
 
4.3 
MMF 
        PR 
        NR 
OUT OF 4 
1(25) 
3(75) 
 
8 
12 
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RELAPSE 
           During followup, 13 patients out of  93 who achieved remission (CR or 
PR) had relapse at a mean duration  of  2.8 years. Eighty percent of them had 
prior  partial remission only .Table  6 gives details about relapse. 
 
Table 6 NUMBER (%) 
TOTAL NO OF PATIENTS 13(14%) 
PATIENTS CHARACTERISTIC  
MALE  
ATTAINED CR  
ATTAINED PR   
ALONE ON STEROIDS 
ON CYCLOSPORINE 
 
10(80) 
3(20) 
10(80) 
11(85) 
2(15) 
TREATMENT 
 2nd   DOSE OF  STEROID 
 
5(38) 
OUTCOME 
PARTIAL REMISSION 
NO REMISSION 
 
 
2(40 ) 
3(60) 
 
HISTOLOGICAL SUBTYPES OF FSGS 
Among 170 FSGS patients, Not Otherwise Specified  was the commonest  
, present in 96(56%)  , followed by tip variant in  41(24%) , perihilar type  in 16 
(10%) and cellular 15(9%) . Only two (1%) patients had collapsing FSGS, 
reached ESRD in 2.2 years. Clinico-pathological details according to Columbia 
classification are noted in Table 7.  
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Table 7 NOS (96) TIP (41) CELLULAR 
(15) 
PERIHILAR 
(16) 
MEAN AGE 29 30 29 30 
MALE /FEMALE 59/37(61/39) 29/12(70/30) 10/5(66/34) 11/5(69/31) 
PROTEINURIA 
MEAN 
NEPHROTIC 
 
4.4 
81(84) 
 
4.1 
29(70) 
 
3.9 
14(93) 
 
3.2 
9(56) 
HEMATURIA 29(30) 13(37) 6(40) 3(19) 
MEAN SERUM CREATININE 1.16 1.32 1.17 1.6 
RENAL FAILURE 16(16) 6(15) 4(26) 6(25) 
HYPERTENSION 41(43) 14(34) 5(33) 9(56) 
ANEMIA 36(38) 10(24) 9(60) 4(25) 
HYPERCHOLESTEROLEMIA 52(54) 21(51) 9(60) 9(61) 
HYPOALBUMINEMIA 52(54) 28(68) 99(60) 6(38) 
IFTA 33(34) 14(34) 2(13) 5(31) 
ARTERIOSCLEROSIS 51(53) 25(60) 9(60) 7(44) 
REMISSION 
                   PR 
                   CR 
                  NR 
 
24(25) 
23(24) 
49(51) 
 
7(16) 
22(54) 
12(30) 
 
5(34) 
4(26) 
6(40) 
 
3(19) 
5(31) 
8(50) 
AT FOLLOWUP 
CKD(<60ml/min) 
ESRD 
 
50(52) 
17(17) 
 
13(32) 
3(7) 
 
10(33) 
1(6) 
 
7(44) 
4(25) 
 
Among subtypes , perihilar variant present with less microhematuria , 
nephrotic proteinuria compared to NOS(p<0.001) and cellular variety(p<0.001). 
Cellular variant present more with renal failure (p<0.05)  at presentation Vs tip 
variant and more  arterial hyalinosis in renal biopsy (p 0.03)  compared to 
perihilar lesion. Hypoalbuminemia (p 0.001) was commonly seen in tip lesion 
and hypertension in perihilar variant (p 0.007) compared to other groups. 
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Interstitial fibrosis and tubular atrophy  were seen more in NOS (p 0.007) Vs 
cellular  variant. Complete remission was seen more in tip variant (p 0.001) 
when compared to others. Less remission and progression to CKD was 
increasingly noted in NOS type compared to tip lesion (p 0.003 & p 0.009  
respectively).   
PREDICTORS OF POOR RESPONSE TO TREATMENT  
            By univariate analysis of different variables , factors that predict poor 
renal response as denoted by nil remission are detailed in Table 8. 
Table 8-FACTORS         p-VALUE
AGE < 20 YRS 
MALE 
NEPHROTIC PROTEINURIA AT ONSET 
PERSISTENT NEPHROTIC AT 3 MONTHS 
PERSISTENT NEPHROTIC AT  6 MONTHS 
RENAL FAILURE AT ONSET 
PERSISTENT RENAL FAILURE AT 3 MONTHS 
PERSISTENT RENAL FAILURE AT 6 MONTHS 
HYPERTENSION 
 0.9 
 0.8 
 0.01 
<0.001 
<0.001 
 0.03 
 0.05 
 0.01 
0.5 
RENAL BIOPSY 
GLOMERULOSCLEROSIS > 5 % 
ARTERIOSCLEROSIS 
INTERSTITIALFIBROSIS&TUBULAR ATROPHY(> 30%) 
PRESENCE OF FOAM CELLS &MESANGIAL CELLULARITY 
IgM STAINING 
 
0.8 
0.12 
0.007 
 
0.5 
0.4 
0.3 
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Table  9-Independent variables Coefficient Std. Error rpartial t P 
(Constant) -0.6428      
FIBROSIS 0.1700  0.06926 0.1888 2.455 0.0152 
RENAL_FAILURE_AT_3M 0.1345  0.09958 0.1052 1.351 0.1786 
RENAL_FAILURE_AT_6M 0.01073  0.007639 0.1093 1.404 0.1621 
NEPHROTIC 0.08663  0.07975 0.08478 1.086 0.2789 
NEPHROTIC_AT_3M 0.4151  0.07683 0.3898 5.404 <0.0001 
NEPHROTIC_AT_6M 0.4263 0.1029 0.3087 4.143 0.0001 
 
              By multivariate analysis , persistent nephrotic proteinuria at 3rd and 6th 
month and presence of  interstitial fibrosis and tubular atrophy > 30 % in renal 
biopsy are the independent predictors of poor renal response given in  Table 9. 
FACTORS PREDICTING CKD PROGRESSION AND POOR RENAL SURVIVAL  
Analysis of factors like  age < 20 years , male gender,nephrotic 
proteinuria at onset, persistent nephrotic proteinuria at 3 months and 6 months, 
renal failure onset,persistent renal failure at 3 months and 6 months,presence of 
anemia  and hypertension , interstitial fibrosis and tubular atrophy > 30% and 
arteriosclerosis in renal biopsy and no remission after treatment were done 
using  univariate to predict the progression to CKD and occurence of ESRD 
(poor renal survival). Subjecting the statistically significant variables to linear 
regression multivariate analysis,independent risk factors were derived. Details 
are given in table 10 with p values(<0.05 were considered significant).  
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Table 10-FACTORS CHRONIC KIDNEY DISEASE ENDSTAGE RENAL DISEASE 
 UNIVARIATE MULTIVARIATE 
( P VALUE) 
UNIVARIATEMULTIVARIATE 
      (P VALUE) 
AGE < 20 YRS 
MALE 
NEPHROTIC PROTEINURIA 
PERSISTENT NEPHROTIC 
AT 3 MONTHS 
PERSISTENT NEPHROTIC 
AT  6 MONTHS 
RENAL FAILURE AT ONSET 
PERSISTENT RENAL 
FAILURE AT 3 MONTHS 
PERSISTENT RENAL 
FAILURE AT 6 MONTHS 
HYPERTENSION 
ANEMIA 
NO REMISSION 
INTERSTIAL FIBROSIS & 
TUBULAR ATOPHY 
ARTERIOSCLEROSIS 
0.65 
0.05 
0.05 
0.001 
 
0.001 
0.04 
0.0006 
 
0.0001 
0.03 
0.006 
<0.0001 
0.0006 
 
0.1 
_ 
0.2 
0.9 
0.4 
 
0.2 
0.6 
0.1 
 
0.6 
0.5 
0.03 
0.0005
0.05 
 
-- 
0.9 
0.4 
0.6 
0.2 
 
0.004 
0.2 
0.04 
 
0.0001 
0.3 
0.04 
0.0001 
<0.0001 
 
0.2 
_ 
-- 
-- 
-- 
 
0.04 
-- 
0.4 
 
0.2 
0.3 
0.1 
0.02 
0.0001 
 
--- 
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SURVIVAL ANALYSIS  
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 Comparison of survival curves (Logrank test) 
Endpoint: Observed n 26.0 117.0 
Expected n 19.3 123.7 
Chi-square 3.3648  
DF 1  
Significance  P = 0.0536  
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Survival analysis were done using Kaplan Meier method . Overall renal 
survival was 78 % at  3 years and  54 % at 5 years. Renal survival was 
significantly higher in patients presented with normal renal function compared 
with those with renal failure at presentation  with  66 % Vs  42  % at 5 years 
.Renal survival difference with or without nephrotic proteinuria at onset was  39 
% Vs  69 % at 5 years and is given below. 
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LOG RANK TEST-P (0.01) 
In our study, renal survival at 5 years with  complete remission  was 69%, 
partial remission was  49% and no remission  was 42%.There  was no 
significant difference between those achieve partial remission and nil response.  
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DISCUSSION 
                         
Focal segmental glomerulosclerosis is a pathological process  of various 
etiologies rather than a single disease entity, characterized by  presence of 
segmental sclerotic lesions with focal involvement. The incidence of FSGS in 
adults is increasing recently 62  .One study  showed  FSGS as the cause  of 
idiopathic FSGS in 15% of  adult patients  in 1970s, whereas in 35% of patients  
in 1990s  and other studies  showed prevalence of 30-35% in patients above  60 
years 63 . 
                                
Among 170 patients, 111( 65 %)  were  males ,similar proportion of 
males compared to other studies. Mean age in our study was 29.2 ± 13.1 years, 
predominantly in the age group of 20-40 and 17 % were above 40 years,while 
mean age in other studies was 35 to 45 years. Nephrotic proteinuria and 
microhematuria was present in 79 % and 30 % respectively. Approximately 
75% of children and 60% of adult patients with FSGS present with nephrotic 
syndrome at as initial presentation 54. 
 
.Macro-hematuria was present in two patients. Hypertension was present 
in 41 % and renal insufficiency (Crcl < 60 ml/min/1.73m2)   in 20 %. Around , 
27 patients (16%) were smokers. Anemia was prevalent in 36%. 
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Hypercholesterolemia and hypoalbuminemia were seen  in 91 patients (54%) 
and 97 patients (57%) respectively . Renal function at presentation depends on  
the severity of  nephrotic syndrome and the duration of disease diagnosis and  is  
seen in 20–25% 64 . 
 
Singh et al 44 showed hypertension in 42.2% , gross hematuria in 36.4%, 
micro- hematuria  in 63.6%, azotemia at the time of presentation in 37.5% . 
Mean proteinuria was 5.53   ±   2.89 gm / day while in our study it was 4.26 ± 
1.9 gm /day . Taheri et al reported  mean systolic BP  of  121.19 mm Hg , dia-
stolic BP  of 77.52 mm Hg , serum creatinine of  1.18  mg/dL, plasma albumin 
of 3.29  g/dL,  and  GFR of 87.18 mL/min while in our study it was 132 mm 
Hg, 84 mmHg ,1.24 mg/dl , 3.4 mg/dl and 85.8 ml/min respectively. 
 
                                Adequate renal biopsy specimen (> =10 glomeruli) was 
present in 71%. Global glomerulosclerosis was not seen in 38 % of patients. 
Mesangial hypercellularity and intraglomerular foam cells were present in 11% 
and 26 % respectively.  Significant interstitial fibrosis and tubular atrophy was 
present (> 25% of cortical parenchyma)  in 29 % of patients. Hyaline 
arteriosclerosis was seen in 94 patients (55%) . Total of 90 patients (53 %) 
showed IgM positivity  and 56 patients (33%)  had  C3 positivity in 
immunofluorescence. Those patients with IgG and IgA positivity in renal 
biopsy were excluded from our study  as other glomerular diseases like 
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membranous nephropathy ,IgA nephropathy ,diabetic nephropathy ,lupus 
nephritis and alport’s syndrome also present as  FSGS in renal biopsy.  
Schwartz et al 29 showed IgM positivity in 17 % and mesangial cellularity in 16 
%. Global scars and synechiae to Bowman's capsule was shown to be 
prognostic factor in one study. Proteinuria induces integrin expression in the 
tubules and prognosis can be determined by integrin expression by 
immunochemical staining. Presence of mesangial hypercellularity and 
hyalinosis has been suggested as predictors for lower remission rate 66 . 
  
All our  patients received oral prednisoslone 1 mg per kg per day for 
atleast  six  months , tapered and stopped  within one month . They were started 
on ACEI or ARB  or both and escalated to a maximum tolerable dose , out of 
170 patients , 14 (8%) were off  these drugs due to intolerance. Benefit of ACEI 
and ARB may be due to inhibition of angiotensin II thereby inhibiting activation 
of TGF-b and matrix expansion. 
 
Apart from steroids , six patients received oral cyclophosphamide, three 
received cyclosporine , two received tacrolimus and four received MMF for 
steroid resistance. Dose of cyclophosphamide is 2 mg/kg for 12 weeks and that 
of cyclosporine is 5 mg/kg daily for 12 months in addition to low dose steroids. 
During followup the incidence of renal failure (Crcl < 60 ml/min/1.73m2)s was  
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12% at   3 months,13 % at 6 months ,19 % at 12 months ,42 % at 3 years and 60 
% at 5  years.Totally 49 % had renal failure at mean followup of 4.32 years. 
Incidence of ESRD is 29 (17%) at mean time of 4.32 years and two patients 
died due to uremia at mean time of  2.4 yrs.  
 
On steroid therapy, out of 170 patients 54 patients (32%) had complete 
remission at mean time  of 6.4 months, 39 (23%) had partial remission at mean 
time of 5.7 months and 77 (45%) had no remission. Partial remission occured 
earlier at mean time of 3.4 months (p 0.002) in those who achieved complete 
remission. Hence early partial response is the predictor of complete remission. 
Agarwal et al showed 58% remission (31% CR and 27% PR ) to steroids in 
biopsy proven FSGS patients with nephrotic syndrome . Korbet et al reported  a 
50% response  with  oral prednisolone. Miyata et al 67 reviewed 32 FSGS 
patients with steroids alone . Forty-four per cent had CR, 12% had PR and 44% 
had nil response.  In a study by Pei et al ,44 %  had complete remission in  
median duration of 6 months with steroids in elderly patients (> 60 years of age) 
with FSGS. No relapses were noted and none had ESRD in the group who had 
remission .  
 
None of  the  patients on cyclophosphamide therapy had remission either 
partial  or complete.Two patients (66%)  on cyclosporine  and two patients 
(100%) on tacrolimus and one patient (25%) on MMF had partial remission  
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and  none had complete remission. The prospective Regional 
Glomerulonephritis Registry Study 68 followed 95 adult and pediatric patients 
with FSGS, for a mean period  of 61 months and showed a remission rate of  39 
5 in adults  prolonged  therapy  with steroids . Ponticelli et al reported an overall 
, 70% remission (complete or partial ) and had  stable renal function at 10 years  
with prolonged  corticosteroids or immunosuppressive therapy. 
 
A study cohort from the Toronto Glomerulonephritis Registry include  
281 nephrotic FSGS patients .Out of them , 55  had   CR, PR noted in 117, and 
109 had no remission over a median follow-up of 65 months . One study 
described 52% of complete remission, 22% of partial remission and 26% of no 
response after 8 weeks of steroid therapy in  primary FSGS patients with 
nephrotic proteinuria. Even partial remission was  found to be an independent 
predictor of  renal survival off dialysis. 
 
Relapse occurred in 13 out of 93 patients (14%) who achieved remission 
(CR or PR) at a mean time of 2.8 years during followup compared in other 
studies where relapse rate was reported as high as 40%. Males (80%) had more 
relapse than females. Three patients (20%) and 10 patients (80%) respectively 
had complete and partial remission prior to the relapse. Two patients who 
achieved partial remission with cyclosporine had relapse during tapering of 
drug. Totally five patients  who experienced relapse were treated with second 
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dose of steroids ,out of which two (40%) achieved partial remission at a mean 
time of 5.2 months and three didnot respond to treatment. A study showed 
relapse of 56 % after PR and associated with  rapid decline in renal function 
compared with those who did not achieve PR69 . Female sex and nadir of 
proteinuria during remission time were associated with a sustained remission. 
 
Studies have suggested that cyclophosphamide and other cytotoxics may 
induce remission in additional 10% of  patients who were steroid unresponsive 
70-72. Cyclosporine is the only agent  tested for the benefits   by  randomized  
controlled  trials  in adults with FSGS 73 .The main drawback of  CSA is that  40 
to 75% experience a  relapse within two  months of  stopping or tapering  the 
drug. Patients on CNI therapy for at least one year before tapering experience 
sustained remission 74 . Cattran et al. 75 reported that 70% had remission by 26 
weeks with   40% relapse at one year in patients who received CSA . 
 
In a recent study of  25 patients with steroid-resistant FSGS, who were 
treated with tacrolimus (0.15 mg/kg/day) and  full dose prednisone  for atleast  8 
weeks, CR was achieved in 40% and PR  in 8% .Median time to remit was  
three months. Seventy six percent of patients  relapsed after stopping  
tacrolimus76 . 
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 Briggs et al. reported a   remission rate of 66% with MMF in steroid 
ressistant FSGS 77. A study by Choi et al. noted the steroid sparing effect of 
MMF in these patients 78. MMF is an alternative to CNIs in patients with 
progressive renal failure due to its negligible side effects on renal 
hemodynamics and metabolic profile.  
 
Complications occur in FSGS as a part of disease or due to drugs. 
Corticosteroids may expose the patient to high risk of infections,  
hyperglycemia, cosmetic side effects, and hyperlipidemia . Osteoporosis is  
another potential  adverse   effect  seen  frequently  and  is severe in 
postmenopausal women .Venous thrombosis(4%) and cellulitis (7% ) due to 
anasarca occurred as complications of  disease process . Infection (48%) was  
the commonest complication followed by cushingoid features (24%)  and 
hyperglycemia (4%) in our study. 
 
Not Otherwise Specified is the commonest subtype of  FSGS (according 
to working classification by D’Agati) and was  present in 96 (56%) ,followed by 
tip variant in 41(24%), perihilar type  in 16 (10%), cellular in 15(9%) and 
collapsing (1%). Thomas et al.  showed a prevalence of  cellular variant  to be  
3%.  In one study, FSGS not otherwise specified was the most common subtype 
(44.6%), followed by perihilar FSGS (24.6%), collapsing (13.8%), tip (12.3%) 
and cellular FSGS (4.6%) 79. The incidence in another series was tip lesion 
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(37%), NOS (32%) ,cellular variant (3%), perihilar variant (26%) , and 
collapsing variant(5%). 
 
Among subtypes, perihilar variant present with less microhematuria 
(19%) , nephrotic proteinuria (56%)  compared to NOS  and cellular type. 
Cellular variant present more with renal failure at presentation (26%)  Vs tip 
variant and more  arterial hyalinosis (60%) in renal biopsy compared to perihilar 
lesion. Hypoalbuminemia was commonly seen in tip lesion (68%)  and 
hypertension in perihilar variant (56%)  compared to other groups. Interstitial 
fibrosis and tubular atrophy (34%) were seen more in NOS Vs other variant. 
Complete remission (54%) and better renal survival was seen more in tip variant  
when compared to NOS  and  perihilar variant similar to previous published 
studies . Less remission and progression to CKD was increasingly noted in NOS 
type (52%) compared to tip lesion. 
 
The tip variant was associated with highest remission rate in our study of 
70 % while other studies also showed higher remission rate of   57 – 60 %. Two 
patients with collapsing FSGS didnot respond to treatment, reached ESRD in 
2.2 years. One study in 43 collapsing FSGS patients by  Valeri and colleagues  
revealed nil response to oral prednisolone and rapid fall in kidney function.  
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There was no difference in mean age at presentation and gender ratio 
within the subtypes. Mean proteinuria in perihilar variant was 3.3 gm/day 
compared to other variant with mean of  4.2 gm/day.Mean serum creatinine was 
also higher in perihilar variant compared to others (1.5 mg/dl Vs 1.22 mg/dl). 
 
By multivariate analysis , persistent nephrotic proteinuria at 3rd and 6th 
month and presence of  interstitial fibrosis and tubular atrophy > 30 % in renal 
biopsy are the independent predictors of no remission after treatment. Presence 
of nephrotic proteinuria at onset, renal failure at onset, persistent renal failure at 
3 months and 6 months were significant risk factors for poor treatment response 
predicted by univariate model but not by linear regression analysis. Most studies 
demonstrated that  presence of significant  interstitial fibrosis was the only 
independent predictive factor for response to treatment. 
 
One study from Europe showed  a spontaneous remission rate of 23% in 
patients with FSGS not treated with immunosuppression 80 .This may be due to  
various aetiology of FSGS  , better  BP  control  and  liberal use of 
antiproteinuric measures. Achievement of  sustained CR or atleast  PR ,retard 
progression rate and improving renal survival are important goals in 
management of FSGS.   
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Risk factors like male gender, nephrotic proteinuria at onset, persistent 
nephrotic proteinuria at 3 months and 6 months, renal failure onset, persistent 
renal failure at 3 months and 6 months,  presence of hypertension , anemia , 
interstitial fibrosis and tubular atrophy of  > 30%  in renal biopsy and no 
remission after treatment predict the progression to CKD at mean followup.Of 
this last three factors were the independent predictors. Absence  of  remission 
was the single most strong predictor for the progression to chronic kidney 
disease. 
 
Predictors for the occurrence of ESRD  at mean followup time were 
persistent nephrotic proteinuria at 6 months, persistent renal failure at 3 months 
and 6 months, presence of anemia , interstitial fibrosis and tubular atrophy of  > 
30%  in renal biopsy and no remission after treatment . Persistent nephrotic 
proteinuria at 6 months, interstitial fibrosis and tubular atrophy > 30%  and no 
remission after treatment were found to be independent risk factors. Strong 
predictor for  progression to  ESRD in our study was the presence of  interstitial 
fibrosis and tubular atrophy > 30%  in renal biopsy. Rydel et al found that  the 
extent of interstitial fibrosis  predicted the development of ESRD  81 . Wehrman 
et al found that interstitial fibrosis, not serum creatinine, had independent 
predictive value for progression to ESRD 56 . Korbet et al showed that serum 
creatinine > 1.3 mg/dl, range of proteinuria and interstitial fibrosis > 20 % were 
positive predictors of occurrence of ESRD.  
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Overall renal survival by  Kaplan Meier survival analysis was 78 % at  3 
years and  54 % at 5 years. Renal survival was significantly higher in patients 
presented with normal renal function compared with those with renal failure at 
presentation with 66 % Vs  42  % at 5 years. Renal survival difference with or 
without nephrotic proteinuria at onset was  39 % Vs  69 % at 5 years . Renal 
survival differ from those who respond to treament than those who didnot 
achieve remission (either complete or partial). But in our study, renal survival at 
5 years for complete remission  was 69%,for partial remission 49% and for  no 
remission 42 %.There is no significant difference between those achieve partial 
remission and nil response.Therefore, attaining complete remission significantly 
improves renal survival.  Renal survival rates  were 68.6% and 27.3% at five 
and 10 years respectively in a study by Singh and colleagues 42 . Cameron et al  
82  reported five and 10 year survival rates  as 70% and 40%  respectively. 
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CONCLUSION 
 
1. Males were  more commonly affected with FSGS  and  mean age at 
presentation  in our study  was  29.2 ±  13.1 years. 
2. The incidence of  nephrotic proteinuria was 79% and microhematuria was 
30 % .Hypertension was present in 41 % and renal insufficiency in 20 %. 
3. Complete  remission  was seen in  32%  at a mean time  of 6.4 months, 
partial remission  in  23 %  at a  mean time of 5.7 months  and  45%  had no 
remission. 
4. Partial remission occurred earlier at a mean time of  3.4 months in those 
who achieved complete remission. 
5. Relapse  rate  was 14%  at a mean time of 2.8 years during followup . 
6. FSGS- NOS was the commonest subtype of  FSGS  (present in 56%) 
,followed by tip variant in 24% , perihilar type  in 10%, cellular in 9%  and 
collapsing  in 1%. 
7. Cellular variant present more with renal failure and more  arterial hyalinosis 
in renal biopsy. 
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8. Perihilar variant present with less microhematuria ,nephrotic proteinuria  
and more with hypertension compared to other variants. 
9. Tip lesion  present with more hypoalbuminemia  and   complete remission 
(54%)  and renal survival  was seen more in this  variant. 
10. NOS was characterised by more  interstitial fibrosis and tubular atrophy 
,less remission and more progression to CKD compared to tip  variant. 
11. Persistent nephrotic proteinuria at 3rd and 6th month and presence of  
interstitial fibrosis and tubular atrophy > 30 % in renal biopsy are the 
independent predictors of  poor response to treatment. 
12. Male gender, nephrotic proteinuria at onset, persistent nephrotic proteinuria 
at 3 and 6 months, renal failure  at onset, persistent renal failure at 3 and 6 
months, presence of hypertension , anemia , interstitial fibrosis and tubular 
atrophy of  > 30%  in renal biopsy and no remission after treatment predict 
the progression to CKD. 
13. Absence  of  remission was the single most strong predictor for the 
progression to chronic kidney disease. 
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14. Persistent nephrotic proteinuria at 6 months, interstitial fibrosis and tubular 
atrophy > 30%  and no remission after treatment were found to be 
independent risk  factors and presence of  interstitial fibrosis and tubular 
atrophy > 30%  in renal biopsy was the strong  predictor  for development 
of ESRD in our study. 
15. Overall renal survival was 78 % at  3 years and  54 % at 5 years.  Renal 
survival  difference with or without nephrotic proteinuria at onset was  39 % 
Vs  69 % at 5 years. 
16. Renal survival was significantly higher in patients presented with normal 
renal function compared with those with renal failure at presentation with 
66 % Vs  42  % at 5 years. 
17. Renal survival at 5 years for complete remission was  69%,partial remission 
was  49% and no remission was 42 %  . 
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S.NO NAME AGE SEX PROTESR.CR SBP DBP HB T.C SR.ALNO. O GLO TYPE FIBROSART HIGMC3 COMPL PCR 3MCR3M PCR.6 CR.6MPCR 12CR.12 TIME ‐  TIME ‐cRELAPSE ETIME CR.3Y CR.5Y FOLLO ESRD
1 NAVANEETHAM 56 F 4 1.1 156 80 7.6 190 4 24 3 NOS 50 Y N N 2 1.2 0.5 1.1 0.3 1 12 16 1.3
2 RAJESH 15 M 4.5 0.9 130 80 7.7 160 3.2 9 TIP 20 N 1 1.1 1.3 12
3 PARASURAMAN 45 M 1.8 1.2 110 70 14.5 200 3.1 9 2 NOS 10 N 1+ N 1.1 0.8 0.08 0.9 0.1 0.9 2 4 1 1.2 12
4 DURAIRAJ 29 M 2.8 1.1 140 80 12.6 206 3.8 2 NOS 10 Y 2+ N 0.9 0.8 0.12 0.8 0.11 1 1.2 1.3 13
5 HAJIRA 22 F 2.8 0.9 140 100 9.9 210 3.5 2 CELLULAR 20 N 2+ N 2 0.9 1 1 0.8 1 24 1.2 1.2 13
6 ANTONY 37 M 3.4 0.7 136 98 12 245 3.3 3 TIP 0 N N N CUSHING 0.8 0.7 0.1 0.9 0.08 1 4 8 1 1 15
7 GOPIKRISHNAN 36 M 4.3 1.7 190 90 11 300 3.4 11 3 NOS 50 Y 2+ N CUSHING 2.4 2.3 1.1 2.5 1 2.8 24 3.4 4.5 7 6
8 KAMALA 28 F 7.7 0.8 128 80 9.8 258 3.3 9 NOS 50 Y 1+ N 2.3 0.9 1.2 1 0.8 1.2 12 28 1.2 1.5 14
9 NARAYANAN 40 M 3.9 0.9 130 90 11 196 4 5 1 CELLULAR 20 N 1+ N 1.9 0.8 1.1 1.2 0.1 0.8 24 34 1 1.2 13
10 FARID AHAMED 18 M 5.8 0.8 90 70 12.8 230 3.2 10 2 TIP 20 N N N CUSHING 0.3 0.8 0.08 1 0.1 1 2 5 2 2,4 1.2 1.3 14
11 SARAVANAN 47 M 3.1 0.9 100 70 13.9 245 3.3 4 NOS 0 N 2+ 2+ 2 0.9 1 1 1 1 12 20 2
12 SANKAR 37 M 2.6 0.7 110 70 13.2 300 4 1 NOS 30 N 1+ N 3 1 3.2 1.2 2.1 1.9 1.9 3 14 14
13 VELAYUTHAM 14 M 4.5 0.8 110 70 12.8 245 2.9 20 CELLULAR 20 N 1= 2+ 2 0.8 0.8 1 0.12 1 14 24 1.1 1.4 16
14 MOHANDOSS 18 M 3.8 0.9 110 70 11.5 279 4 15 TIP 20 Y 1+ 4+ CUSHING 0.8 1 0.18 1 0.1 1.1 12 20 1 6 1 1 8.5
15 RAJASEKAR 13 M 3.2 0.9 110 70 13.8 180 3.7 6 NOS 0 N N N 1.2 1 0.3 1 1 1 10 22 1 3
16 POONGULALI 30 F 2.6 2.2 180 90 12 180 3 2 TIP 50 N 2+ N CUSHING 1 2.1 0.5 2.4 1 3.4 10 4.5 5 6 5.5
17 JAMUNA 40 F 4.1 0.7 150 90 10.8 345 3.4 4 NOS 20 Y N N ACNE 2.3 0.8 1.2 1 1 1 3 1
18 MUTHU 35 M 5.6 1.1 140 100 11 133 3 20 NOS 0 N N N 0.8 0.8 0.15 0.8 0.12 1 2 3 1
19 MANJULA 37 F 5.46 0.8 150 90 12 217 4 10 1 PERIHILAR 20 N 1+ N CUSHING 1.2 0.8 0.3 1 0.2 1 3 5 1.2
20 GOVINDHAN 19 M 3.7 0.7 110 70 14 245 4.2 4 1 NOS 0 N N N 0.3 0.8 0.3 0.8 0.2 0.8 1 3
21 SAMRUTH BEGAM 42 F 3.4 1 140 90 11 234 3.3 16 6 NOS 20 N 1+ 1+ 0.8
22 NAGAN 18 M 6 1.5 160 100 13.2 209 3.7 20 PERIHILAR 10 N N N 0.8
23 BALAMANI 29 F 4.22 1 120 90 9.8 197 4 9 1 CELLULAR 20 Y 1+ 1+ 0.3 1 0.12 1 0.1 1.1 1 2 1.1 1.4 10
24 RAJENDRAN 40 M 4.3 0.8 130 90 11 245 3.4 8 1 NOS 0 N N N 0.2 0.8 0.12 0.8 0.12 1 2 2.5 1.2
25 MOHANA 25 F 2.7 0.9 110 70 10.2 250 3.4 6 NOS 40 Y 1+ 1+ 0.5 1 0.3 1 0.2 1 4 6 2 2,4 1 1.1 6
26 SASIKALA 26 F 3.76 0.9 140 100 8.8 260 3.4 7 CELLULAR 10 Y N N 3 1 3.2 1 2.9 1 NO 1.3 1.5 5
27 KOWSALYA 49 F 2.6 1 150 90 13.2 270 4 7 4 PERIHILAR 30 Y N 1+ 2.5 1.1 2.5 1.2 2 1.5 NO 2.2 6 6 5
28 KRISHNAMOORTHY 23 M 2.34 1 120 90 9.8 195 3.3 7 NOS 0 N N N 2.3 1 2.2 1.2 2 1.2 NO 1.3 1.7 12 9
29 BHARATHY 40 F 3.3 0.9 120 80 10 255 4 7 TIP 20 N 1+ 1+ 3 1 2.9 1 3 1.2 NO 2.1 3.1
30 VIJAYALAKSHMI 33 F 1.6 2.1 150 90 8.8 216 3.5 4 PERIHILAR 30 Y N N 2 2 1.2 2 1.1 2 6 2.9 3 12 9
31 AYYANAR 21 M 5.3 1.1 110 80 11.4 189 3.5 16 1 CELLULAR 10 Y N N 0.8 1 0.2 1 0.12 1 2 4 1.1 1.1 16
32 SARASWATHY 27 F 2.9 1.2 160 100 9.2 234 3.7 12 4 NOS 20 Y N 1+ 1.2 2 1.1 1.9 1 2 6 1.1
33 RAMAN 33 M 3.4 1 140 90 10 234 3.1 20 2 CELLULAR 20 Y N 1+ 2.3 1 1.5 1 1 1.1 6
34 BABU 43 M 4 1 140 90 11 212 3.5 12 2 NOS 10 Y N N 2 1 2 1.1 1.9 1 NO 1.4 1.5 13
35 EDISON 28 M 3.7 1 120 80 11.2 200 3.3 9 NOS 20 Y N N 3.3 1 3.4 1 2.8 1.1 NO 1.4 3 5 5
36 SAROJINI 30 F 3.4 1 150 90 11 190 3.6 14 CELLULAR 20 Y 2+ 3+ CUSHING 3 1 2.9 1 2.9 1.2 NO 1.3 2.2 9
37 REENA 30 F 3.1 1 150 90 11 234 3.3 6 1 NOS 30 Y 1+ 2+ CUSHING, 2.9 1 2.9 1.1 2.6 1.1 NO 1.6 1.9 9
38 PONRAJ 16 M 2.7 0.7 130 90 13 190 3.7 8 1 NOS 20 Y 1+ 2+ 3 1 1 1 0.8 1.1 6 1.2 1.6 9
39 BHASKAR 31 M 3 1.2 140 96 9.2 180 3.5 15 2 NOS 10 Y N N 0.6 0.8 0.12 1 0.1 1 2 4 1 1.2 8
40 ANNADURAI 35 M 3.3 0.9 110 70 13.9 188 4 6 NOS 10 Y 2+ 3+ 1.8 1 0.9 1 1 1 6 2 4,6 1 1.5 8
41 VEDIAPPAN 20 M 2.7 1.2 110 80 12.6 260 3 8 TIP 0 Y N N 2.5 1 2 1 2.2 1 NO 1.2 1.5 8
42 KRISHNAN 40 M 4 1 110 70 12.8 290 2.8 7 TIP 50 Y 1+ 3+ 0.5 0.89 0.13 0.9 0.1 1 2 4 1 1.1 8
43 VISWANATHAN 15 M 4 1 110 70 9.2 188 4 7 2 NOS 20 Y 1+ 2+ 2.5 1 2 1 2 1 NO 1.5 1.9 8
44 SRINIVASAN 37 M 3.5 1 110 70 13 220 3 12 NOS 0 Y 1+ N 0.2 1 0.12 0.9 0.12 1 1 1.5 1 1.2 8
45 SUDAMANI 47 M 3.75 1 160 100 11 280 3.2 9 1 NOS 50 N 1+ 2+ 2.2 1 2.3 1 2 1.2 NO 1.9 3 8 6
46 SHANMUGAM 26 M 3.7 1 110 80 11.4 188 3.6 8 NOS 0 N 1+ N 0.9 1 0.12 1 15 1.1 2 6 1.2 1.2 8
47 SIVASAKTHI 13 F 4 1 110 70 11 190 3.3 8 NOS 10 N N N 2.2 1 1.4 1 1 1 6 1 3 1.6 3 6
48 PALANI 26 M 3.4 1 120 80 13.8 170 4 4 NOS 10 Y 1+ 1+ 3 1 3.1 1 2.7 1 NO 1.5 1.9 6
49 BENAZIR PARVEEN 15 F 6.32 1 120 80 10.3 190 3.4 7 NOS 50 Y 1+ 1+ 3 1 3.4 1.3 3 1.7 NO 1.9 2 6 6
50 SRINIVASAN 27 M 5.4 1.1 120 80 12.8 150 4 13 1 NOS 0 N 1+ N 3.8 1 3.5 1.1 3 1.2 NO 1.7 2 6
51 SHAMSUNDAR 13 M 2.4 1 120 80 11 190 3.6 5 NOS 0 N N N 1.2 1 0.2 1 0.12 1.1 2 4 1.2 1.1 6
52 RAJASEKAR 32 M 5.7 1 150 90 11.4 154 3.4 17 1 TIP 30 Y 1+ 2+ SEPSIS 5.5 1 5 1.1 4.5 1.2 NO 1.5 1.7 6
53 LALITHA 27 F 4 1 160 90 14 202 3.3 5 NOS 0 N N N 3 1 3 1 3 1.1 NO 1.7 5 6 5
54 PARASURAMAN 27 M 3.29 1.1 160 90 14.2 176 3.4 12 NOS 30 Y 2+ 2+ CUSHING 3 1 2.9 1 2.3 1.2 NO 1.2 1.7 6
55 THARANI 16 F 4.5 1.2 160 100 11 190 3 7 1 NOS 30 Y 2+ 3+ ACNE 3.3 1 2.9 1.1 2.2 1.1 NO 1.9 2.2 6
56 LIVIYA 17 F 3.7 1.1 90 60 12.8 130 3.9 11 PERIHILAR 0 N 2+ 4+ ACNE 2.1 1 1.1 1 0.8 1.1 6 1.2 4
57 GUNASUNDARI 16 F 5.4 0.9 130 90 11 240 4 3 NOS 20 Y 2+ N 1.1 1 0.12 1 0.2 1 2 4 1.3 4.5
58 KALAIARASI 23 F 7 0.9 140 90 12 267 3.5 10 NOS 20 Y 1+ N TB ADENIT 4.5 1 4 1 3.7 1.2 NO 1.6 4.5
59 NEELAMEGAM 58 M 3.46 1.8 180 100 11 230 3 10 3 PERIHILAR 40 Y 1+ N 3.5 1.9 3.2 2 3 2.3 NO 5.7 4.5 3.5
60 SUDHANDHIRAJ 42 M 4 1.5 150 100 10 345 3.1 12 2 NOS 30 Y 1+ N 0.8
61 KRISHNAMOORTHY 20 M 4.5 1.2 140 90 12 220 3.3 3 TIP 20 Y 1+ 1+ 2.5 1 1.7 1.1 1.2 1.1 6 1.7
62 THANGABATHRAKA 28 F 5 0.8 120 80 14 230 3.4 10 NOS 10 Y N N 2.6 1 1.8 1.1 1.7 1.2 5 1.7
63 VASANTHI 41 F 3.7 1 120 80 11 220 3.5 11 NOS 10 Y 1+ N 2.8 1.1 2.5 1.2 2.2 1.2 NO 1.9
64 PRAVEENKUMAR 14 M 6 1 120 70 12 240 2.8 13 NOS 10 Y 1+ N 3.8 0.9 3.4 1 3 1.2 NO 2
65 NATARAJAN 70 M 5 1.4 160 80 11 230 3.4 4 CELLULAR 40 Y N N CUSHING 3.4 1.4 3 1.3 2.9 1.4 NO 2
66 KANAGARAJ 18 M 2.7 0.8 130 90 14 195 3.5 18 TIP 30 Y N N CUSHING 2 1.1 2 1 0.12 1.1 3 4 1 1.5 2
67 KUMARESAN 17 M 5.73 1.5 120 90 14 140 3.2 20 TIP 10 N 1+ 1+ CUSHING 2.5 1 1.7 1.1 1.6 1 4 1.4
68 BALU 16 M 4.1 1.2 140 90 13 200 3 9 PERIHILAR 10 N N N DISCON 3 1.1 3.1 1.1 3 1 NO 1.3
69 RAMAN 33 M 3.5 2.7 130 90 11 210 3.1 20 CELLULAR 10 N N 1+ 3.1 2 3.2 1.4 2.7 2 NO 1.7
70 MANIVANNAN 35 M 5.8 2.3 140 90 13.8 220 3.4 11 TIP 15 N N N 1.2 1 0.2 0.9 0.12 1 2 3.5 1.3
71 PASUPATHY 15 M 1.2 0.8 120 80 12.8 170 3.8 21 NOS 10 N N N 1.3 1 1 1 1.1 1 NO 1.3
72 SARASWATHY 26 F 6.1 1.3 120 80 11.2 240 3.4 12 4 NOS 30 N N N 3 1.2 3 1.2 2.9 1.3 NO 2 4.8
73 YAMUNA 13 F 5.3 0.7 130 80 11 190 3.7 4 NOS 20 N 1+ 1+ 0.8 LOST
74 VALARMATHY 35 F 6.5 1.8 170 100 11 230 3.6 16 1 NOS 20 Y N N 2.7 1.7 3 2.2 2.3 3 NO 3.4 4.8 4.5
75 GOPI  25 M 4.5 1.4 130 90 12 210 3.9 4 TIP 40 Y 2+ 1+ 1.2 1 0.2 1 0.2 1 2 3.5 4.8
76 SANGEETHA 13 F 5 1.1 110 70 13 200 3.6 26 1 NOS 10 N N N 3 1.1 2.9 1.1 NO
77 VASANTHA 28 F 4 1 140 80 12 196 4 20 1 TIP 20 N 1+ 2+ 2 1 0.2 1 0.12 1 2 4 1.4 2.4 8
78 SUNDARI 30 F 3.7 1.4 140 80 9.8 180 3 6 TIP 20 N 1+ 1+ 3 1.1 2.8 1 2.6 1.1 NO 1.1 1.2 8
79 DILLIGANESH 14 M 3 0.9 120 80 12 180 3.6 4 NOS 20 N N N 3 1.2 2.9 1.1 2.5 1.3 NO 1.7 2.2 8 6
80 GOPI 17 M 2.6 0.9 120 80 12.6 220 4 5 PERIHILAR 20 N 1+ 1+ CUSHING, 3 1.2 2.3 1.3 2.5 1.9 NO 5 5 5
81 MANI  45 M 3.2 1.3 150 80 8.2 188 3.6 9 1 PERIHILAR 10 N N N 1 1 0.2 1 0.2 1 2 4 1.2 1.5 8
82 SRINIVASAN 34 M 2.9 1 140 90 12 196 3.6 7 1 PERIHILAR 10 N 1+ N 0.9 1 0.12 1 0.2 1 1 3.5 1.3 1.8 8
83 MANIKANDAN 16 M 4.5 0.8 110 70 12 290 3 8 NOS 10 N 1+ N 0.8 1 0.12 1 0.2 1 2 5 1.4 1.9 8
84 SUSEELA 40 M 3 1.2 110 70 11.5 180 3.2 24 2 NOS 10 N 1+ N 1 0.9 0.15 1 0.12 0.9 2 5 1 1.1 8
85 SAIRAM 13 M 5.9 0.7 120 70 12.1 247 3 6 NOS 10 N 2+ N CUSHING, 3.5 0.8 2.9 0.8 3 1 NO 2.2
86 KANNAN 30 M 2.6 2 130 80 13.8 120 3.4 10 1 TIP 20 Y N N 2.8 1.4 1.9 1.4 1.5 1.3 6 2.2
87 KATHIRAVAN 20 M 4.7 1.3 130 100 14.9 310 3 6 TIP 20 Y N 2+ CUSHING, 3 1.2 2.9 1.1 2.5 1.3 NO 2.6
88 PAPPAYEE 55 F 2.6 1.4 160 90 9 270 3.8 3 1 NOS 20 N N N 0.8
89 RAGHUPATHY 47 M 3.7 1.1 110 80 8.8 240 3.1 4 1 TIP 40 N 1+ N 1.2 0.9 0.12 1 0.12 1 2 3.5 2.6
90 MARIASELVAM 30 F 4.3 0.7 110 70 12.5 249 3.7 15 1 NOS 40 Y 3+ 2+ CUSHING 2.5 1 2.2 1 2 1 NO 2.6
91 VARADHAN 64 M 1.6 2 120 80 15.8 270 3.4 9 1 TIP 30 Y 2+ N CUSHING 1.2 1 1 1 1.2 1 3 2.6
92 SHANATHI 35 F 4.3 3.5 160 100 10 118 3.7 3 1 NOS 60 Y 4+ 4+ 3 3 2.6 3.8 2 4 2 4.5
93 MADHAN 19 M 4.4 1.4 170 100 6 130 4 14 2 NOS 40 Y N N 3 1.3 2.8 2 3 2.1 NO 2.9 2.4
94 SYED 23 M 3.2 0.9 170 120 11 220 3.5 16 1 NOS 20 N 2+ N 0.8
95 GOMATHY 33 F 3 0.8 140 90 11.8 130 4 9 1 NOS 30 N N N 0.2 0.8 0.12 0.9 0.1 0.9 1 3 1.9
96 IMRANKHAN 17 M 4 0.8 120 80 11 230 3.5 8 TIP 20 N N N 1.9 0.8 0.2 0.9 0.2 0.9 2 6 1 5
97 VIRUTHAMBAL 42 F 4.6 1.9 150 90 10 230 3.3 10 2 NOS 30 N N N 3 1.9 2.9 2 2.5 2.1 NO 2.9 3
98 PRASANNA 16 F 4 1.6 150 90 10 140 3.3 17 1 NOS 30 N 2+ N 2.9 2 2.8 2.1 2.5 2.2 N0 3 5
99 SALEEM 19 M 2.7 0.7 130 80 12.5 220 4 18 1 TIP 20 N 2+ N 1.2 0.7 0.2 1 0.2 1 1 4 1 3
100 JEYANTHI 40 F 6.1 2 150 90 12 210 3.5 9 2 TIP 20 Y N N 1 1.5 0.2 1 0.2 1 2.3 4.5 2
101 MURALI 14 M 4.3 1 130 80 11 220 3.4 10 2 NOS 30 Y N N 3 1 2.9 1.1 2.5 1.1 NO 1.2 5
102 SALEEM 13 M 4.1 0.7 120 80 11.8 470 3.1 9 2 PERIHILAR 30 Y N N 1 0.8 0.23 1 0.2 1.1 2 4 1.9
103 SANGEETHA 13 F 5 1.3 110 70 13 220 3.6 26 2 NOS 10 N 1+ N 1 1 0.2 1.1 0.2 1 3 5 0.9
104 VATCHALA 45 M 3.1 0.7 110 70 12 260 3 10 2 CELLULAR 20 N 2+ 2+ 2 1 0.9 1 0.8 1.1 6 1.6 6.9
105 VINOTH 23 M 3.7 1.8 150 90 10 240 3.4 10 1 NOS 20 N 1+ N 2 1.6 1.7 1.5 1 2 5 6 3 3
106 GOTHANDARAMAN 38 M 5.3 2.1 150 100 12.8 120 3.4 6 3 NOS 50 N N N 2 1.8 1.8 2 1 2.1 NO 1
107 ARUNKUMAR 37 M 8 1.2 140 90 12 220 3.2 10 TIP 0 N N N 0.12 0.8 0.2 0.8 0.2 0.8 1 2 1
108 GAJENDRAN 52 M 9 3.4 160 100 9.8 120 3 5 2 NOS 20 Y N N 2 2 1.8 2 5 0.8
109 ILAYADASAN 18 M 5.5 1.1 150 90 9 220 3.4 9 1 NOS 20 Y 1+ N 2.3 1.2 2.2 1.2 2.2 1.4 NO 1.7 6.4
110 MARIA LOUIS 30 M 2.6 1.2 110 70 14 294 3.5 9 2 TIP 10 Y 1+ N 2.2 1 2.2 1 2 1.1 NO 1.5 3
111 KUMARAVALLI 46 F 4.8 1.8 140 90 10 130 3.8 15 6 NOS 40 Y 1+ N 0.8
112 SHANMUGAM 50 M 6.5 1.8 140 90 14 130 3.4 8 NOS 20 Y N N 3 1.4 2.6 1.7 NO 0.9
113 RAJIVGANDHI 23 M 5.7 0.9 140 90 12 296 3.5 19 6 PERIHILAR 10 Y N N UTI 2.9 1.2 3 1.2 3 1.3 NO 1
114 PADMANABAN 45 M 8 1.2 140 90 9.5 220 3.7 5 NOS 10 N 2+ N 1.6 1.1 1.5 1.2 1.2 1.2 6 1
115 MUTHUANAND 22 M 5.7 0.9 150 100 13 210 3.5 14 NOS 0 N N N 2.4 1.1 2.3 1.1 2.1 1.2 NO 1
116 AMIRTHAVALLI 24 M 8 1.1 120 80 12.5 120 4 8 NOS 0 N N N 2 1 1.5 1 1.2 1.1 5 1
117 RAJAM 40 F 4.4 0.9 130 90 12.8 128 3.6 16 NOS 20 N N N 3.2 1 3 1 2.8 1.1 NO 1.2
118 AMUDHA 26 F 5.4 0.9 110 70 11 176 3.9 5 1 NOS 10 N 2+ 3+ 4 1 3 1 2.5 1.1 NO 1.1
119 MUNUSAMY 60 M 1.8 5 140 80 11 120 3.7 4 1 TIP 40 Y N 2+ 2 4 2.4 4.1 2 4.2 NO 4 3.3 3
120 RAVI 37 M 8.9 0.8 130 80 11.5 289 3.5 24 NOS 10 Y 1+ 1+ 3 1
121 ABINASH 16 M 3.2 0.7 130 90 13.8 140 3.2 10 NOS 20 Y 1+ N 2.5 1 2.2 1 2.1 1 NO 2.6
122 NARASIMMAN 18 M 3.6 0.6 120 90 11 300 4 9 NOS 10 N N N 2.5 1 2.2 1.2 2.2 1.2 NO 1.4 5.5
123 SATHISHKUMAR 15 M 5.3 0.9 110 70 14.2 547 3.8 12 CELLULAR 0 N 2+ 3+ 3 1
124 JAYAPAUL 43 M 2.33 7 130 70 12.8 156 3.2 29 PERIHILAR 10 N N 2+ 1.6 4 0.07 1 0.12 1 2 5 1 5.5
125 LALITHA 20 F 3.7 0.9 120 70 8.5 190 3.2 7 PERIHILAR 10 N N N 2.2 1.1 2.1 1.2 2.2 1.2 2.5
126 SYED KAFIL 47 M 3.9 0.9 150 90 13 120 4.1 7 NOS 10 N N N 2.9 1.1 3 1.3 3.1 1.9 NO 2.5 2.5
127 CHELLATHAI 27 F 4.3 1.6 120 80 10 395 3.7 14 2 NOS 10 Y 1+ 2+ 4.3 1 3 1.1 2.3 1.2 2.5
128 SEENIVASAN 35 M 5.2 1 120 80 15 120 3.4 15 PERIHILAR 20 Y 2+ 2+ 3.4 1 3 1.2 2.8 1.3 NO 2.5
129 AYYAPAN 18 M 4.1 1 130 80 12 295 3.3 14 CELLULAR 20 Y N N 3 1
130 MUNEESWARAN 16 M 6.2 1.3 120 80 13.8 120 3 14 11 COLLAPSE 60 Y N N CUSHING, 6.2 1.4 4 NO 0.8 0.9
131 RAJI  50 M 3.8 0.8 130 80 10.8 200 3.1 10 1 TIP 20 Y 1+ N 1 1 0.2 1 0.12 1.1 2 4 1.2 1.2
132 SEKAR 32 M 4 1 140 90 12 126 4 7 TIP 50 Y 1+ 1+ CUSHING 3.5 1.1 3.5 1.1 3 1.3 NO 1.4 1.5
133 VIJAYANAND 21 M 2.6 1.1 110 70 13.5 144 3.8 2 PERIHILAR 15 Y 3+ 3+ CUSHING 3 1.2 1 1.1 1 1.3 6 1.4 1.4
134 RAVI 19 M 3.4 1.3 120 80 14 146 4 42 CELLULAR 20 Y N N 3 1.2 3 1.3 2.8 1.3 NO 1.8 2
135 ALAMELU 35 F 4.1 1.3 130 80 12 168 3.8 15 TIP 20 N 3+ 3+ 2.5 1.1 2.2 1.2 2.2 1.3 NO 1.5 1.5
136 BALASUBRAMANI 21 M 4 1.5 150 90 11 170 3.4 14 COLLAPSE 30 Y N N 3 1.5 2.7 1.5 2.2 1.9 NO 7 6 2.5
137 VIVEKANANDAN 35 M 2.4 1.3 160 100 11 166 3.8 3 TIP 20 N 1+ N 1 1.2 0.1 1.1 0.12 1.1 2 4 1.2 1.2
138 MOHAMMED HUSS 31 M 4 2 160 100 9 190 3.2 8 NOS 40 Y N N 3 2 2.9 2.3 2.5 3 NO 2.9 2.5
139 SUNDARI 45 F 5.8 1.2 140 90 12 210 3 8 TIP 20 Y 1+ N GLYCEMIA 0.21 1 0.07 1.2 0.2 1.2 1.5 3 1.3 1.3
140 VENUGOPAL 18 M 2.9 1.4 120 80 11 200 3 7 1 TIP 20 Y 2+ 3+ CUSHING 2.8 1.7 2.5 1.5 2.3 1.2 NO 1.3 1.3
141 MALA 37 F 4.6 1.3 120 80 10.2 270 3.2 4 TIP 10 Y 1+ N 0.2 1 0.12 0.9 0.12 0.9 1 2 2 1,2 1.2 1.3
142 BHUVANESHWARI 31 F 4.6 1 120 80 13.5 130 4 8 NOS 0 N N N SEPSIS 3.2 1 3 1 2.9 0.1 NO 1.1
143 SHANMUGAM 60 M 5 3 150 80 12 140 3.3 22 NOS 50 Y 1+ 2+ 3 3 2.8 3.1 2.7 3.3 NO 4
144 MANIKANDAN 24 M 5 1.1 110 70 12 380 4.6 15 NOS 10 N 1+ 1+ 0.8
145 USHA 30 F 3.4 0.8 150 100 10 230 4.1 9 NOS 30 Y N N 0.8
146 ELAKIYA 22 F 3.2 0.9 180 110 11 220 3.4 23 NOS 15 N N N 0.8
147 VIJAYAKUMAR 17 M 4.2 1.3 110 70 10 150 3 9 NOS 40 Y N N 1 1.3 0.2 1.3 0.2 1.4 2 5 3 5 4
148 DINESH 20 M 3.9 1.2 130 80 13 150 3.8 9 TIP 20 Y 3+ 2+ 3 1.3 2.8 1.4 3 1.8 NO 3.1 7 5
149 SELVARAJ 22 M 4 2.1 110 80 10.5 170 3.4 6 TIP 0 N 1+ 1+ 1 1 0.2 0.9 0.2 0.9 2 5 1 4 0.8 1
150 MURALI 14 M 3.5 1.3 130 80 8 120 3 13 5 NOS 40 Y 1+ 1+ SEPSIS 3 1.4 2.9 1.5 2.9 1.7 NO 7 7
151 DHAMU 42 M 6.3 1.9 130 80 12 130 3 6 NOS 20 Y 1+ 1+ 2.5 1.4 2.4 1.6 2.5 2.4 NO 6 7
152 KUMAR 16 M 2.7 0.8 100 70 13.2 180 3.4 6 NOS 20 N N N 0.2 0.8 0.12 1 0.1 1 1 2 0.9 1
153 LAKSHMI 24 F 6.4 0.9 130 80 11.5 360 3 12 TIP 30 Y 3+ 3+ 2.5 1 2.9 1 2.5 1 NO 1.1 1.1
154 AMSA 40 F 3.9 1.4 90 60 13 240 3.2 5 NOS 10 Y 1+ N 0.2 1 0.12 1 0.2 1 1 2 2 2,3 1.2 1.2
155 SHAHUL HAMEED 45 M 5.6 1.8 150 90 12 180 3.4 3 NOS 20 Y N N 3 2 2.9 2.1 2.5 3 NO 9 7
156 SATHYARAJ 16 M 5.2 0.8 110 70 14 240 4 7 NOS 20 Y 2+ 3+ 0.2 0.8 0.12 0.8 0.12 0.9 1 2 0.9 0.9
157 BHUVANESHWARI 21 F 4.8 0.8 110 70 10.8 200 3.4 9 4 NOS 30 Y N N HEMETEM 3 1 3 1 2.5 1 NO 1.3 1.3
158 FOWRIA BEGAM 20 F 3.7 2 110 80 9.8 180 3.5 19 CELLULAR 45 Y N N 2.5 2.1 2.6 2.3 2.2 3 NO 4.5 7 3.8
159 POWN 40 F 6.6 1.3 150 100 10.8 140 4.5 3 TIP 0 Y 2+ 2+ 0.2 0.8 0.12 0.9 0.12 0.9 1 3 1 1
160 KARTHIKEYAN 14 M 2 0.9 100 70 12.8 180 3.8 5 TIP 10 Y N N 0.12 0.9 0.12 0.9 0.2 1 1 3 1 1
161 VIJAY 26 M 7.3 1.8 130 80 12.8 447 3 4 NOS 40 Y N N 2.1 2 1.5 2.1 1 2 4 3 3
162 TOUFIQ AHAMED 17 M 7 0.8 130 80 12 438 3 8 NOS 0 Y 1+ 1+ 2.5 1 2.2 1.2 2.2 1.3 NO 1.4 1.5
163 RATHINAM 47 F 5.4 0.8 110 80 9 160 3.7 7 NOS 0 N N N 2.5 0.8 2.2 0.9 2.3 0.8 NO 1
164 RAJESHWARI 27 F 3.7 0.8 150 90 12 210 3 17 NOS 20 N 1+ N 2.3 0.8 2.2 0.9 2.2 0.9 NO 1.2
165 USHA 16 F 5.1 0.9 110 70 14 200 3.2 4 TIP 20 Y N N 2 1 0.2 0.9 0.12 0.9 2 4 1
166 ELUMALAI 40 M 5.9 1.5 150 90 15 150 3 13 TIP 20 Y N N 1 1.3 0.12 1 0.1 0.9 2 4 1
167 SUSEELA 26 F 2.7 0.8 150 90 13.5 140 3.2 16 TIP 0 Y 2+ N 1.5 1 1 0.9 1 0.9 4 1.2 1.4
168 SAKTHIVEL 20 M 5.5 1.4 140 90 10.4 498 3.8 12 NOS 40 Y N N ABD TB 3 1.2 2.8 1.4 12.9 2 NO 2.2
169 KUMAR 29 M 4 1 140 90 11.8 200 2.3 4 NOS 30 Y N N 2 1.1 1.2 1 1 1.1 5 1.1
170 KUBENDRAN 27 M 4.3 1.2 120 70 13.9 230 3.2 12 NOS 0 N N N 2.4 1
Your digital receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
Paper ID 313660380
Paper title Epidemiological profile ,clinico-pathological correlation and treatmentresponse in adult patients with primary focal segmental glomerulosclerosis
Assignment
title Medical
Author Dhanapriya Jeyachandran 16102002 D.M. Nephrology
E-mail priyamdhana@yahoo.co.in
Submission
time 20-Mar-2013 05:42PM
Total words 8489
First 100 words of your submission
Epidemiological profile ,clinico-pathological correlation and treatment response in adult patients with
primary focal segmental glomerulosclerosis INTRODUCTION Focal segmental glomerulosclerosis
(FSGS) is a common cause of nephrotic syndrome, accounting for 10% to 35% of nephrotic
syndrome in adults. Focal segmental glomerulosclerosis is a pattern of injury defined by a segmental
scar, that involves some but not all glomeruli.The prognosis of FSGS in untreated is bad , with 50%
patients reach end-stage renal disease (ESRD) at eight years.FSGS account for 20% of dialysis
patients and is a common cause of ESRD. The incidence of FSGS has been increasing in recent
years. Kitiyakara et al....
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